On-demand biomanufacturing of protective conjugate vaccines
Open Access
- 5 February 2021
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (6), eabe9444
- https://doi.org/10.1126/sciadv.abe9444
Abstract
Conjugate vaccines are among the most effective methods for preventing bacterial infections. However, existing manufacturing approaches limit access to conjugate vaccines due to centralized production and cold chain distribution requirements. To address these limitations, we developed a modular technology for in vitro conjugate vaccine expression (iVAX) in portable, freeze-dried lysates from detoxified, nonpathogenic Escherichia coli. Upon rehydration, iVAX reactions synthesize clinically relevant doses of conjugate vaccines against diverse bacterial pathogens in 1 hour. We show that iVAX-synthesized vaccines against Francisella tularensis subsp. tularensis (type A) strain Schu S4 protected mice from lethal intranasal F. tularensis challenge. The iVAX platform promises to accelerate development of new conjugate vaccines with increased access through refrigeration-independent distribution and portable production.Keywords
Funding Information
- National Science Foundation (CBET 1159581)
- National Science Foundation (CBET 1264701)
- National Science Foundation (MCB 1413563)
- David and Lucile Packard Foundation
- Defense Threat Reduction Agency (HDTRA1-15-10052/P00001)
- Camille and Henry Dreyfus Foundation (Teacher Scholar Program)
This publication has 92 references indexed in Scilit:
- Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance dataThe Lancet Infectious Diseases, 2012
- Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine componentGlycoconjugate Journal, 2012
- Vaccination: rattling the supply chainBulletin of the World Health Organization, 2011
- Production of Secretory and Extracellular N-Linked Glycoproteins in Escherichia coliApplied and Environmental Microbiology, 2011
- Production of glycoprotein vaccines in Escherichia coliMicrobial Cell Factories, 2010
- Delivery of foreign antigens by engineered outer membrane vesicle vaccinesProceedings of the National Academy of Sciences of the United States of America, 2010
- Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensisVaccine, 2009
- Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvantCellular and Molecular Life Sciences, 2008
- Potential Role for Toll-Like Receptor 4 in Mediating Escherichia coli Maltose-Binding Protein Activation of Dendritic CellsInfection and Immunity, 2007
- Definition of the bacterial N-glycosylation site consensus sequenceThe EMBO Journal, 2006